Molecular Imaging via Novel Application of Fluorescent Lectins Permits Rapid Endoscopic Identification of Dysplasia in Barrett's Esophagus

Abstract

Introduction Early detection of oesophageal adenocarcinoma (AC) or high grade dysplasia (HGD) improves prognosis but may missed at endoscopy. Hypothesis Glycosylation alterations in the progression to AC could be detected using lectins to allow endoscopic imaging with a wide field of view. Aims (1) Determine if and when glycan gene expression and lectin binding alters in progression to AC. (2) Determine whether fluorescently labelled lectins can detect dysplastia in biopsies and at endoscopy. Methods Gene set enrichment analysis of glycan pathways was applied to gene expression data from squamous oesophagus (NE), Barrett9s oesophagus (BE), LGD and HGD (n=57). Human samples (n=21) were applied to evanescent and ratiometric lectin arrays (n=45 and 78). External validation used lectin histochemistry (n=80). Fresh whole biopsy lectin staining was performed at the bedside (n=33) using WGA-680 and assessed using IVIS 200. Whole oesophagus imaging used WGA-488 with endoscopic excitation at 395–475 nm and detection at 500–630 nm. Specificity of WGA binding was confirmed using N-acetyl glucosamine in a competition assay and by preincubation with α (2→3,6,8,9) neuraminidase. Statistics: Jonckheere-Terpstra test for trend, Bonferroni correction to ANOVA and a one-sided paired t test for the specificity assays. Results Coordinated changes in glycan expression occur at every stage of the progression to AC (p Conclusion Surface glycans alter in the progression from BE to AC and lead to altered lectin binding. WGA validated to the point of successful endoscopic visualisation of high grade dysplasia. Further studies are needed to determine the sensitivity and specificity of this molecular imaging tool in vivo.